This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lushang Life Services Co., Ltd. agreed to acquire Shandong Lujian Property Management Limited from Lushang Freda Pharmaceutical Co.,Ltd. for CNY 4.9 million. CI
Lushang Health Industry to Sell 90% Stake in Healthcare Subsidiary for 21 Million Yuan MT
Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Lushang Health Industry Plans Selling Real Estate Assets to Controlling Shareholder MT
Lushang Health Plans to Sell Real Estate Assets to Controlling Shareholder or Affiliates CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Lushang Life Chairman Steps Down MT
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Lushang Life Shares Slump 15% at Open, Joins Wave of Lackluster Hong Kong Debutants MT
Lushang Development's Property Manager Arm Raises Nearly $18 Million in Hong Kong IPO MT
Lushang Development's Property Manager Arm Launches Up to $34 Million Hong Kong IPO MT
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Lushang Health Industry Development Co.,Ltd. cancelled the acquisition of an unknown minority stake in Shandong Focuschem Biotech Co., Ltd. CI
Lushang Health Industry Development Co.,Ltd.(XSSC:600223) added to S&P Global BMI Index CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Lushang Property Co.,Ltd. Announces Dividend of A Share for Year 2019, Payable on July 13, 2020 CI
Chart Lushang Freda Pharmaceutical Co.,Ltd.
More charts
Lushang Freda Pharmaceutical Co Ltd is a China-based company mainly engaged in the manufacture and sale of pharmaceuticals and cosmetics. In terms of medicine, the Company is committed to the research and development, production and sales of Chinese patent medicines, chemical medicines, and health foods. Its products cover five fields: orthopedics, gynecology, internal medicine, ophthalmology, and pediatrics. The Company's cosmetic products involve aroma therapy, aroma skin care, aroma health care, aroma health care and other fields. In terms of raw materials, derivative products, and additives, the Company is mainly engaged in the production of hyaluronic acid raw materials.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.98 CNY
Average target price
11.75 CNY
Spread / Average Target
+47.24%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600223 Stock
  4. News Lushang Freda Pharmaceutical Co.,Ltd.
  5. Lushang Development's Property Manager Arm Launches Up to $34 Million Hong Kong IPO